Luca Dezzani

475 total citations
18 papers, 112 citations indexed

About

Luca Dezzani is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Luca Dezzani has authored 18 papers receiving a total of 112 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Luca Dezzani's work include Renal cell carcinoma treatment (11 papers), Renal and related cancers (9 papers) and Cancer Genomics and Diagnostics (8 papers). Luca Dezzani is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Renal and related cancers (9 papers) and Cancer Genomics and Diagnostics (8 papers). Luca Dezzani collaborates with scholars based in Italy, United States and United Kingdom. Luca Dezzani's co-authors include Qasim Ahmad, Jackie Han, Hans Gelderblom, Manuela Schmidinger, Axel Le Cesne, Sebastian Bauer, Patrick Schöffski, Haralabos P. Kalofonos, Yulia Hirschberg and Christian Kollmannsberger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Luca Dezzani

18 papers receiving 112 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luca Dezzani Italy 7 76 52 51 27 18 18 112
Francesca Daniel Italy 7 56 0.7× 123 2.4× 29 0.6× 68 2.5× 6 0.3× 21 180
G. Koumakis Greece 7 27 0.4× 94 1.8× 15 0.3× 37 1.4× 5 0.3× 21 149
Patricia Maeda United States 7 54 0.7× 82 1.6× 45 0.9× 28 1.0× 7 0.4× 16 168
Elias Pintus United Kingdom 6 107 1.4× 55 1.1× 28 0.5× 32 1.2× 5 0.3× 13 148
Aparna Pallavajjalla United States 7 116 1.5× 55 1.1× 138 2.7× 39 1.4× 33 1.8× 10 226
Donata Sartori Italy 6 36 0.5× 72 1.4× 22 0.4× 51 1.9× 17 0.9× 18 126
Coralia Bueno Spain 8 78 1.0× 111 2.1× 36 0.7× 63 2.3× 6 0.3× 22 170
Sonja Heibl Austria 7 53 0.7× 103 2.0× 25 0.5× 60 2.2× 21 1.2× 21 155
Elena Aguirre Spain 8 68 0.9× 117 2.3× 34 0.7× 63 2.3× 6 0.3× 22 183
Sucheta More India 6 99 1.3× 69 1.3× 17 0.3× 34 1.3× 7 0.4× 24 141

Countries citing papers authored by Luca Dezzani

Since Specialization
Citations

This map shows the geographic impact of Luca Dezzani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Dezzani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Dezzani more than expected).

Fields of papers citing papers by Luca Dezzani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Dezzani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Dezzani. The network helps show where Luca Dezzani may publish in the future.

Co-authorship network of co-authors of Luca Dezzani

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Dezzani. A scholar is included among the top collaborators of Luca Dezzani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Dezzani. Luca Dezzani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cesne, Axel Le, Sebastian Bauer, George D. Demetri, et al.. (2019). Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer. 19(1). 794–794. 22 indexed citations
2.
Sternberg, Cora N., Robert J. Motzer, Thomas E. Hutson, et al.. (2019). COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 17(6). 425–435.e4. 13 indexed citations
3.
Muniz, David Queiroz Borges, Hongbo Yang, James Signorovitch, et al.. (2019). Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Advances in Therapy. 36(12). 3446–3457. 2 indexed citations
4.
Procopio, Giuseppe, Aristotelis Bamias, Manuela Schmidinger, et al.. (2019). Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 17(3). e526–e533. 8 indexed citations
5.
Schmidinger, Manuela, Aristotelis Bamias, Giuseppe Procopio, et al.. (2019). Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). The Oncologist. 24(4). 491–497. 22 indexed citations
6.
Yang, Lin, Anna Alyasova, Dingwei Ye, et al.. (2018). RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC Cancer. 18(1). 195–195. 2 indexed citations
7.
Souza, Paul L. de, Shirley Wong, Sanjeev Sewak, et al.. (2018). Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).. Journal of Clinical Oncology. 36(6_suppl). 648–648. 1 indexed citations
8.
Procopio, Giuseppe, Aristotelis Bamias, Manuela Schmidinger, et al.. (2018). Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study). Annals of Oncology. 29. viii313–viii313. 1 indexed citations
9.
Grünwald, Viktor, D.Y.C. Heng, M. Dror Michaelson, et al.. (2018). Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment. European Urology Supplements. 17(14). e2957–e2957. 1 indexed citations
10.
Hochhaus, Andreas, Philipp le Coutre, L. N. Petrov, et al.. (2017). Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology. 143(7). 1225–1233. 6 indexed citations
11.
Cesne, Axel Le, Sebastian Bauer, George D. Demetri, et al.. (2017). Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses. Annals of Oncology. 28. v530–v531. 1 indexed citations
12.
Bjarnason, Georg A., Christian Kollmannsberger, Qasim Ahmad, et al.. (2017). Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.. Journal of Clinical Oncology. 35(15_suppl). 4574–4574. 6 indexed citations
13.
Tannir, Nizar M., Camillo Porta, Viktor Gruenwald, et al.. (2017). Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis.. Journal of Clinical Oncology. 35(15_suppl). 4572–4572. 3 indexed citations
14.
Kattan, Michael W., Winette T.A. van der Graaf, Thomas Powles, et al.. (2017). Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib.. Journal of Clinical Oncology. 35(6_suppl). 455–455. 3 indexed citations
15.
16.
Hochhaus, Andreas, François‐Xavier Mahon, Philipp le Coutre, et al.. (2015). Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. Blood. 126(23). 4054–4054. 2 indexed citations
17.
Dezzani, Luca, et al.. (2011). Cell fusion in tumor progression: the isolation of cell fusion products by physical methods. Cancer Cell International. 11(1). 32–32. 10 indexed citations
18.
Noris, Patrizia, Iride Francesca Ceresa, Chiara Ambaglio, Luca Dezzani, & Carlo L. Balduini. (2006). Thrombopoietin (TPO) Levels in Inflammatory Disorders with or without Reactive Thrombocytosis.. Blood. 108(11). 1111–1111. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Daniel Breakdown of academic impact, for papers by G. Koumakis Breakdown of academic impact, for papers by Patricia Maeda Breakdown of academic impact, for papers by Elias Pintus Breakdown of academic impact, for papers by Aparna Pallavajjalla Breakdown of academic impact, for papers by Donata Sartori Breakdown of academic impact, for papers by Coralia Bueno Breakdown of academic impact, for papers by Sonja Heibl Breakdown of academic impact, for papers by Elena Aguirre Breakdown of academic impact, for papers by Sucheta More
Rankless by CCL
2026